Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Early results from new PD-1 targeted immune therapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.12
Views: 3608

Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Suzanne Topalian presented results from an early-stage study showing treatment with the investigational drug BMS-936558.


The drug caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and non-small cell lung (NSCLC) cancers. 


ecancerNews Coverage

Related videos

follow us

WIN 2019

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation